Tibet Aim Pharm (SZSE:002826) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Tibet Aim Pharm LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Tibet Aim Pharm's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.00.

Tibet Aim Pharm's long-term debt to total assets ratio stayed the same from Jun. 2023 (0.00) to Jun. 2024 (0.00).

Tibet Aim Pharm LT-Debt-to-Total-Asset Historical Data

The historical data trend for Tibet Aim Pharm's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tibet Aim Pharm LT-Debt-to-Total-Asset Chart

Tibet Aim Pharm Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Tibet Aim Pharm Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Tibet Aim Pharm LT-Debt-to-Total-Asset Calculation

Tibet Aim Pharm's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )	/	Total Assets (A: Dec. 2022 )
	=	0	/	1018.205
	=	0.00

Tibet Aim Pharm's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	0	/	923.747
	=	0.00

Tibet Aim Pharm (SZSE:002826) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Tibet Aim Pharm LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Tibet Aim Pharm's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Tibet Aim Pharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tibet Aim Pharm Inc (SZSE:002826) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

No. 6, Linqionggang Road, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000

Website

http://www.emyy.cn

Tibet Aim Pharm Inc is the pharmaceutical company based in China. It is mainly engaged in the research and development, production and sales of chemical drugs and proprietary Chinese medicines for common chronic disease such as diabetes and cardiovascular disease as well as medicines for gynecology and obstetrics. The company's products offering includes miglitol tablets, gualoupi injection, nalmefene hydrochloride injection, carbetocin injection; hongjin xiaojie tablets and aceclofenac enteric-coated tablets. The company also expanded its products in the treatment of antibiotic, antiallergic and digestive system.

Executives

Peng Hui	Director
Pang Guo Qiang	Directors, executives
Li Qian Jin	Securities Affairs Representative
Liu Hang	Supervisors

Tibet Aim Pharm Headlines

No Headlines